Skip Nav Destination
Issues
1 August 2014
-
Cover Image
Cover Image
Chin and colleagues found that knockdown or pharmacologic inhibition of AKT2 but not AKT1 induced apoptosis in established tumor spheroids derived from PTEN-deficient prostate, breast, and glioblastoma cell lines, indicating that this isoform is essential for PTEN-deficient tumor survival. AKT2 depletion resulted in upregulation of p21 and BAX and downregulation of insulin-like growth factor 1 receptor; knockdown of p21, but not BAX, rescued apoptosis induced by AKT2 depletion, suggesting that p21 is a downstream target of AKT2. Importantly, although AKT1 silencing exhibited a largely cytostatic effect in prostate cancer xenografts, AKT2 depletion increased p21 levels, stimulated apoptosis, and promoted tumor regression. These results indicate that AKT2 is required for the maintenance of PTEN-deficient tumors and highlight the need for preclinical development of AKT2-selective inhibitors. For details, please see the article by Chin and colleagues on page 942. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
In the Spotlight
Mini Review
Research Briefs
Vulnerabilities of PTEN–TP53-Deficient Prostate Cancers to Compound PARP–PI3K Inhibition
Enrique González-Billalabeitia; Nina Seitzer; Su Jung Song; Min Sup Song; Akash Patnaik; Xue-Song Liu; Mirjam T. Epping; Antonella Papa; Robin M. Hobbs; Ming Chen; Andrea Lunardi; Christopher Ng; Kaitlyn A. Webster; Sabina Signoretti; Massimo Loda; John M. Asara; Caterina Nardella; John G. Clohessy; Lewis C. Cantley; Pier Paolo Pandolfi
Research Articles
NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
Christopher A. French; Shaila Rahman; Erica M. Walsh; Simone Kühnle; Adlai R. Grayson; Madeleine E. Lemieux; Noam Grunfeld; Brian P. Rubin; Cristina R. Antonescu; Songlin Zhang; Rajkumar Venkatramani; Paola Dal Cin; Peter M. Howley
Author Choice
EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing
Joshua M. Francis; Cheng-Zhong Zhang; Cecile L. Maire; Joonil Jung; Veronica E. Manzo; Viktor A. Adalsteinsson; Heather Homer; Sam Haidar; Brendan Blumenstiel; Chandra Sekhar Pedamallu; Azra H. Ligon; J. Christopher Love; Matthew Meyerson; Keith L. Ligon
News in Brief
Research Watch
Apoptosis
Breast Cancer
Drug Resistance
Genomic Instability
Glioblastoma
Immunology
Immunotherapy
Medulloblastoma
Melanoma
Oncogenes
Senescence
Splicing
Stem Cells
Targeted Therapy
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.